Yakujiho Compliance: The Legal Red Lines for Beauty and Skincare in Japan

What Is Yakujiho?

Yakujiho (薬機法) — formally, Japan's Act on Securing Quality, Efficacy, and Safety of Products Including Pharmaceuticals and Medical Devices — is the primary regulatory framework governing product claims for cosmetics, skincare, supplements, health foods, and medical devices sold in Japan. Enacted in 1960 and significantly revised in 2021, it governs:

• Which products qualify as pharmaceuticals or quasi-drugs (医薬部外品): Products requiring individual Ministry of Health, Labour and Welfare (MHLW) registration and approval before they can make specific efficacy claims
• What claims cosmetics can legally make: Strictly limited to 56 permitted efficacy expressions published by MHLW — no others are permissible
• The boundary between regular food and health-functional food categories: Determining which claim frameworks foreign supplement brands can use
• Criminal liability for intentional violations: The 2021 amendment introduced direct penalties for advertising agencies and copywriters who knowingly produce non-compliant materials

The foundational principle of Yakujiho: if your product is not a registered pharmaceutical or quasi-drug, it cannot claim to treat, prevent, cure, or improve any disease or physical condition. This boundary is drawn significantly stricter than in China, Korea, and most Western markets. Enforcement is active and increasingly automated through platform monitoring systems.

Japan's cosmetics market exceeded ¥1.5 trillion (~$10 billion USD) in 2023, with skincare representing the largest segment. Foreign brands account for an increasing share — and compliance violations have become more frequent as cross-border entry accelerates. The MHLW and Consumer Affairs Agency conduct regular monitoring campaigns specifically targeting imported beauty and supplement products.

The 56 Permitted Cosmetic Efficacy Expressions: What This Means in Practice

Japan's Ministry of Health, Labour and Welfare has published a list of 56 efficacy claims that cosmetics sold in Japan may legally make. These claims describe surface-level physical effects on healthy skin — they do not describe therapeutic or medical outcomes. Some key permitted expressions include:

• 皮膚をすこやかに保つ (keeps skin healthy)
• 肌荒れを防ぐ (prevents rough skin)
• 皮膚にうるおいを与える (gives skin moisture)
• 肌をひきしめる (tightens skin)
• 日焼けによるシミ・ソバカスを防ぐ (prevents spots and freckles caused by sunburn) — only for products with SPF certification

Critically, the permitted list does not include: whitening (as in eliminating existing pigmentation), wrinkle reduction, collagen stimulation, eczema improvement, acne treatment, or any expression that implies disease treatment or prevention.

Many foreign brands entering Japan translate existing copy from Chinese or English — "whitening formula," "anti-aging," "reduces fine lines," "repairs damaged skin" — word for word into Japanese. Under Yakujiho, this translated copy constitutes a violation regardless of the source language. The violation travels intact across the language barrier.

Cosmetics and Skincare: Prohibited Claims and Compliant Alternatives

The table above shows the most common prohibited claims and their compliant alternatives. Here are additional examples that frequently appear in foreign brand copy:

The compliant alternatives are not workarounds — they are the standard language framework permitted under Japanese cosmetics law. Foreign brands must design copy within this framework from scratch, not adapt existing copy through translation.

Quasi-Drug Status: What It Enables and What It Costs

Quasi-drugs (医薬部外品) occupy a regulatory tier between cosmetics and pharmaceuticals. Products registered as quasi-drugs can make specific efficacy claims that cosmetics cannot — including whitening (美白), acne prevention (にきびを防ぐ), and hair growth stimulation. The most commercially significant quasi-drug claim in Japan's beauty market is whitening, which requires quasi-drug registration for any product claiming to prevent or reduce melanin-related pigmentation.

What quasi-drug registration requires:

• Application to Japan's Pharmaceuticals and Medical Devices Agency (PMDA): Detailed product formulation disclosure, safety testing data, and clinical evidence for efficacy claims
• Timeline: 12–24 months from application submission to approval in typical cases; complex formulations may take longer
• Cost: Application fees, required testing, and regulatory affairs consulting typically total ¥3–¥10 million per product SKU
• Labeling requirements: Quasi-drug products require specific Japanese-language labeling with MHLW-approved descriptions; packaging changes may be required

Quasi-drug registration makes commercial sense for proven, high-volume SKUs where specific efficacy claims are central to the product's competitive positioning (whitening serums, acne treatments, medicated shampoos). It is generally not worth pursuing for initial market entry testing or for products with uncertain Japan market demand.

Health Supplements and Food Products: A Three-Tier System

Japan's regulatory framework for supplements and health foods is stricter and more complex than its cosmetics rules. The system operates on three distinct tiers, each with different claim permissions:

Tier 1: Regular Food (一般食品)

Most foreign supplements enter Japan as regular food. In this category, zero health or efficacy claims are permitted — including claims common and legal in the brands' home markets:

• "Boosts immune function" — prohibited
• "Supports metabolism" — prohibited
• "Promotes joint health" — prohibited
• "Improves gut health" — prohibited even when supported by clinical data

Regular food labels may only describe the product's nutritional content (protein, vitamins, minerals) — not what those nutrients do in the body.

Tier 2: Functional Claimed Food (機能性表示食品 / FCA)

FCA designation allows specific health function claims after filing a notification with Japan's Consumer Affairs Agency (CAA). Unlike TOKUHO, FCA does not require individual government approval — brands submit their evidence package (typically systematic review or human clinical data) and wait 60 days for the notification to be acknowledged. If no objection is raised, the product can use approved function claims.

FCA claims must be narrowly defined and evidence-based. Common approved FCA claims include: "maintains normal blood pressure," "contributes to memory function," and "reduces body fat." Timeline from FCA filing to market: approximately 3–6 months from submission, plus preparation time for evidence assembly.

Tier 3: Food for Specified Health Uses (特定保健用食品 / TOKUHO)

TOKUHO requires individual product approval from the Consumer Affairs Agency — the most stringent level, equivalent to a limited drug approval process. Timeline: 2–4 years from application to approval. Cost: ¥10–¥30 million+ per product. Appropriate only for brands with substantial Japan market presence and long-term regulatory investment plans.

Compliance Checklist: Before Any Listing Goes Live

Step 1: Confirm Product Classification

Determine your product's regulatory category under Japanese law: regular cosmetic, quasi-drug, regular food, FCA, or TOKUHO candidate. This classification determines which copy framework applies. A regulatory consultant or experienced Japan EC agency should make this determination before copy development begins — not after.

Step 2: Audit All Existing Copy Against Permitted Expressions

Extract every efficacy-related claim from: product title, subtitle, bullet points, full description, A+ Content (Amazon) or Rich PC (Rakuten), product images (including text overlaid on images), and any PDF manuals or instruction cards shipped with the product.

Check each extracted claim against:

• MHLW's 56 permitted cosmetic efficacy expressions (for cosmetics)
• Consumer Affairs Agency's FCA approved claim database (for functional food products)
• Platform-specific content policies (Rakuten and Amazon Japan each have additional prohibited expression lists beyond the statutory minimums)

Machine translation is especially dangerous here: MT tools translate Chinese therapeutic claims into Japanese without compliance filtering. The violation travels intact across the language barrier — "美白成分配合" (containing whitening ingredients) may be legal in China but constitutes a quasi-drug efficacy claim in Japan if used without quasi-drug registration.

Step 3: Rewrite in Compliant Japanese — Not Translate

Replace every non-compliant claim with a compliant Japanese alternative. This requires someone who understands both the intent of the original copy (what consumer benefit it was communicating) and the boundary of compliant expressions available in Japan. The result should read as natural, compelling Japanese product copy — not as a list of legal disclaimers.

Step 4: Image and Visual Content Review

Non-compliant claims in product images — text overlaid on photos, before/after comparison images implying therapeutic effects, infographics with ingredient claim charts — are equally enforceable violations. All product images must be reviewed with the same rigor as text copy. Before/after images for skincare and cosmetics products require particular caution.

Step 5: Post-Launch Quarterly Audit

Rakuten and Amazon Japan conduct periodic compliance audits. Regulatory guidelines can change as MHLW issues new guidance. Review your core SKUs' copy at minimum quarterly — and immediately following any MHLW regulatory update announcements.

Consequences of Yakujiho Non-Compliance

The consequences of Yakujiho violations operate at three levels simultaneously, and all three can occur from a single listing violation:

Platform-Level Consequences

• Listing removal: Immediate upon detection, with no grace period. Listings removed for compliance violations lose all accumulated search ranking and review data — rebuilding from zero.
• Search ranking reset: Even after correcting the violation and reinstating the listing, the product's organic search ranking history may be partially or fully lost.
• Account-level restrictions: Repeated violations on the same store can trigger selling privilege restrictions or permanent account closure on Rakuten and Amazon Japan.

Legal-Level Consequences

• Administrative fines: Japan's Consumer Affairs Agency and MHLW can levy fines of ¥1–¥5 million+ per violation, with separate fines for each non-compliant product listing
• Business suspension orders: For repeat or egregious violations, regulators can order suspension of specific product lines
• Criminal prosecution (post-2021 amendment): The 2021 Yakujiho revision introduced direct criminal liability for advertising agencies and copywriters who knowingly produce non-compliant materials — expanding liability beyond the brand itself

Brand-Level Consequences

Japanese consumers have high sensitivity to brand compliance and safety reputation. A publicized compliance incident — particularly in beauty and health categories where personal safety is implied — can have lasting negative impact on consumer trust. Japanese social media (Twitter/X, Instagram, consumer review platforms) amplifies compliance incidents quickly within category communities.

Action Steps: Building a Yakujiho-Compliant Japan Listing Process

1. Classify your product before writing any Japanese copy — Determine whether your product is a regular cosmetic, potential quasi-drug candidate, regular food, or FCA candidate. This single determination defines everything about what copy is legally permissible.
2. Use MHLW's 56-expression list as your framework — For cosmetics, your copywriter should start from this permitted list and build product benefits around what's allowed, rather than starting from your existing marketing claims and finding compliant substitutes.
3. Commission a line-by-line compliance review from a Yakujiho specialist before launch — Not general legal counsel, not machine translation — a specialist in Japanese pharmaceutical advertising law who understands current enforcement priorities.
4. Review every image for embedded claims — Text overlaid on product photos, comparison imagery, and infographic-style ingredient callouts are as enforceable as written copy. Include images in every compliance audit.
5. Establish a quarterly review cadence post-launch — Assign a specific person or partner responsible for reviewing your Japan listings against current Yakujiho requirements at least once per quarter. Regulatory interpretation evolves; staying current is ongoing work, not a one-time task.
6. Consider quasi-drug registration for whitening claims if it's central to your product positioning — If your product's primary differentiating claim in your home market is whitening or melanin suppression, plan for quasi-drug registration as a 12–18 month investment for your Japan strategy, not an afterthought.

FAQ

Q: My product is compliant in China — does Japan require separate review?
Yes, always. Chinese cosmetics and supplement advertising standards are significantly more permissive than Japan's. Expressions that are standard marketing language in China — "美白" (whitening), "细胞再生" (cell regeneration), "免疫力提升" (immunity boost) — constitute Yakujiho violations in Japan. Compliance in your home market provides no protection in Japan.

Q: Will machine-translated pages pass Rakuten or Amazon Japan review?
Possibly in the short term — platforms do not review every listing in real time before publication. But compliance enforcement operates on a report-and-audit basis: competitor brands in your category routinely report non-compliant competitor listings, triggering audits. Once flagged, removal is typically immediate.

Q: Is registering as a quasi-drug worth it for a new market entrant?
Generally not for initial market entry. The 12–24 month timeline and ¥3–¥10 million+ cost per SKU are significant investments to make before validating Japan market demand. A more practical sequencing: enter Japan with compliant cosmetic-tier copy, validate sales volume and consumer response, then pursue quasi-drug registration for proven top SKUs where specific efficacy claims would provide meaningful competitive differentiation.

Q: Can an influencer or KOL make claims on our behalf that we can't make ourselves?
No. The 2021 Yakujiho amendment extended liability to third parties who make non-compliant claims for products they promote. Influencer marketing materials must comply with the same Yakujiho restrictions as brand-owned product listings. Brief influencer partners explicitly on permissible claim language before any campaign.

Q: What happens if I receive a compliance warning from Rakuten or Amazon Japan?
Treat it as urgent. Respond within 24–48 hours (within the business day is better), correct the specific non-compliant copy identified, and submit a corrected version with a brief explanation of what was changed and why the corrected version is now compliant. Slow or dismissive responses to compliance warnings escalate to account-level action.